Evidence map›Paper›PMID 40476138›Full record

ArticleFrontiers in cardiovascular medicine2025

Missing in action: the genetic mysteries of extremely low HDL cholesterol.

Shoshi Sphitzen, Mordechai Golomb, Mohammad Mowaswes, Refael Bitzur, Smadar Horowitz Cederboim, Ronen R Leker, Marc Gotkine, Itai Chovers, Daniel Schurr, Eran Leitersdorf and 1 more

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Tangier Disease.Current atherosclerosis reports · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shoshi SphitzenLipid Clinic and Center for Cardiovascular Precision Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Mordechai GolombCardiology Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Mohammad MowaswesCardiology Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Refael BitzurThe Bert W. Strassburger Lipid Center, Sheba Medical Center, Ramat Gan, Israel.
Smadar Horowitz CederboimLipid Clinic and Center for Cardiovascular Precision Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Ronen R LekerDepartment of Neurology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Marc GotkineDepartment of Neurology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Itai ChoversOphthalmology Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Daniel SchurrLipid Clinic and Center for Cardiovascular Precision Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Eran LeitersdorfLipid Clinic and Center for Cardiovascular Precision Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Ronen DurstLipid Clinic and Center for Cardiovascular Precision Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: High-Density Lipoprotein Cholesterol (HDL-C) plays a pivotal role in cardiovascular health, acting as a key component in lipid transport and atheroprotection. While low HDL-C levels in the general population are often the result of multifactorial causes, extremely low HDL-C levels (<20 mg/dl) are rare and may be attributed to underlying genetic defects. Mutations in genes such as Methods: In this study, we used exome sequencing on patients with very low HDL-C. Results: We identified three patients with pathogenic mutations associated with genetic low HDL-C syndrome, including Discussion: Each case presented a unique spectrum of clinical phenotypes, systemic complications, and biochemical abnormalities, illustrating the diverse impact of these genetic mutations. We provide a detailed analysis of the clinical and biochemical profiles of these patients, highlighting key aspects of disease manifestation and progression. This report underscores the importance of recognizing and characterizing rare genetic causes of low HDL-C, which may have profound implications for patient care and risk stratification.

Indexed as

ABCA1apoA1HDL-CLCATtangies

Identifiers

PMID40476138
PMCPMC12137234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.